Rybrevant is a cancer medicine used to treat adults with advanced non-small cell lung cancer (NSCLC) whose cancer cells have certain genetic changes in the epidermal growth factor receptor (EGFR) gene. In patients whose cancer has ‘activating EGFR exon 20 insertion mutations’ and has not been treated before, Rybrevant is used in combination with other cancer medicines, carboplatin and pemetrexed. It is also given on its own when previous treatment with platinum-based cancer medicines has not worked well enough. In patients whose cancer has activating EGFR exon 19 deletions or exon 21 L858R substitution mutations, Rybrevant is used in combination with carboplatin and pemetrexed when previous treatments, including an EGFR tyrosine kinase inhibitor, have not worked well enough. Rybrevant contains the active substance amivantamab.
Therapeutic Indication
### Therapeutic indication Rybrevant is indicated: - in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non‑small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI). - in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations. - as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum based therapy.
Therapeutic Area (MeSH)
N/AATC Code
L01FX18
ATC Item
amivantamab
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| amivantamab | N/A | Amivantamab |
EMA Name
Rybrevant
Medicine Name
Rybrevant
Aliases
N/ANo risk management plan link.
